• Mereo BioPharma Group PLC MREO.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -5 cents. The mean expectation of eight analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents to -1 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Mereo BioPharma Group PLC's reported EPS for the quarter was a loss of 1 cent​.

• The company reported a quarterly loss of $7.35 million.

• Mereo BioPharma Group PLC shares had fallen by 17.9% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 92.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Mereo BioPharma Group PLC is $1.50, about 77.2% above its last closing price of $0.34

This summary was machine generated from LSEG data March 23 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)